SCHEMBL24914933

SCHEMBL24914933

CCOC(=O)c1cc(C(N)=O)n(C)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.50
KDM4E B2RXH2 1/20 0.48
CYP1A2 P05177 1/20 0.44
MPO P05164 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
FAAH O00519 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.41
JMJD6 Q6NYC1 1/20 0.41
MMP2 P08253 1/20 0.40
MMP13 P45452 1/20 0.40
MMP14 P50281 1/20 0.40
ATM Q13315 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7698241 0.89 LMNA (0.61) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL1313891 0.86 LMNA (0.52) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL7703521 0.86 LMNA (0.52) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL24914925 0.84 LMNA (0.54) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL1312216 0.83 LMNA (0.50) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL20455602 0.82 MEN1 (0.42) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL8003314 0.81 LMNA (0.47) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL27166556 0.81 LMNA (0.51) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL1233517 0.80 BAZ2B (0.54) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL29092152 0.79 PLA2G10 (0.49) LMNAKDM4EKMT2AMEN1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
EP-4122927-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF ADORA2A, ADORA2B, ADORA3 LMNA 3817/4885RAB9A 2881/4885NPC1 2908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.